+Follow
Maxeyme
No personal profile
18
Follow
18
Followers
0
Topic
0
Badge
Posts
Hot
Maxeyme
06-05
$Cloudflare, Inc.(NET)$
Maxeyme
06-05
$Cloudflare, Inc.(NET)$
Maxeyme
05-12
$Alphabet(GOOGL)$
Maxeyme
05-12
$Cloudflare, Inc.(NET)$
Maxeyme
04-16
$Tesla Motors(TSLA)$
Maxeyme
2023-03-23
$NVIDIA Corp(NVDA)$
.......
Maxeyme
2022-04-23
🍎🍏
Sorry, the original content has been removed
Maxeyme
2022-02-02
20 for 1 what a great news.
Sorry, the original content has been removed
Maxeyme
2022-01-24
Best wishes to IBM holder
IBM Reports Its Earnings Monday. Management’s Forecasts Will Be Key.
Maxeyme
2022-01-03
Accenture
If I Could Buy Only 1 Stock in 2022, This Would Be It
Maxeyme
2021-12-28
One of the most volatile stocks of the year.
Novavax shares dropped another 4% in premarket trading
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3585641054025604","uuid":"3585641054025604","gmtCreate":1622547182548,"gmtModify":1635312196639,"name":"Maxeyme","pinyin":"maxeyme","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/2f6534bff6e2d250aa9f9f44575fda56","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":18,"headSize":18,"tweetSize":22,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖(非转发)","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.07.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.02%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"60.10%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"60.49%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":3,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":442838974001216,"gmtCreate":1749137299634,"gmtModify":1749138476027,"author":{"id":"3585641054025604","authorId":"3585641054025604","name":"Maxeyme","avatar":"https://static.tigerbbs.com/2f6534bff6e2d250aa9f9f44575fda56","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585641054025604","idStr":"3585641054025604"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NET\">$Cloudflare, Inc.(NET)$ </a> ","listText":"<a href=\"https://ttm.financial/S/NET\">$Cloudflare, Inc.(NET)$ </a> ","text":"$Cloudflare, Inc.(NET)$","images":[{"img":"https://community-static.tradeup.com/news/4a8970fd80df2bd90233e5c969a28e4e","width":"1092","height":"1717"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/442838974001216","isVote":1,"tweetType":1,"viewCount":1290,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":442835938181688,"gmtCreate":1749136845035,"gmtModify":1749138475033,"author":{"id":"3585641054025604","authorId":"3585641054025604","name":"Maxeyme","avatar":"https://static.tigerbbs.com/2f6534bff6e2d250aa9f9f44575fda56","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585641054025604","idStr":"3585641054025604"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NET\">$Cloudflare, Inc.(NET)$ </a> ","listText":"<a href=\"https://ttm.financial/S/NET\">$Cloudflare, Inc.(NET)$ </a> ","text":"$Cloudflare, Inc.(NET)$","images":[{"img":"https://community-static.tradeup.com/news/f0d3aa65f643a222b488af45efbe840b","width":"1092","height":"1717"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/442835938181688","isVote":1,"tweetType":1,"viewCount":1082,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":434406816539392,"gmtCreate":1747047180179,"gmtModify":1747047185033,"author":{"id":"3585641054025604","authorId":"3585641054025604","name":"Maxeyme","avatar":"https://static.tigerbbs.com/2f6534bff6e2d250aa9f9f44575fda56","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585641054025604","idStr":"3585641054025604"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/GOOGL\">$Alphabet(GOOGL)$ </a> ","listText":"<a href=\"https://ttm.financial/S/GOOGL\">$Alphabet(GOOGL)$ </a> ","text":"$Alphabet(GOOGL)$","images":[{"img":"https://community-static.tradeup.com/news/3c7e94bf705712cd6c9ee5e71719e7be","width":"1092","height":"1717"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/434406816539392","isVote":1,"tweetType":1,"viewCount":1022,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":434404581007896,"gmtCreate":1747047094273,"gmtModify":1747055860053,"author":{"id":"3585641054025604","authorId":"3585641054025604","name":"Maxeyme","avatar":"https://static.tigerbbs.com/2f6534bff6e2d250aa9f9f44575fda56","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585641054025604","idStr":"3585641054025604"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NET\">$Cloudflare, Inc.(NET)$ </a> ","listText":"<a href=\"https://ttm.financial/S/NET\">$Cloudflare, Inc.(NET)$ </a> ","text":"$Cloudflare, Inc.(NET)$","images":[{"img":"https://community-static.tradeup.com/news/b7630e523e2e2e00233e27a0b269be4f","width":"1092","height":"1717"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/434404581007896","isVote":1,"tweetType":1,"viewCount":1352,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":425180450857416,"gmtCreate":1744813001442,"gmtModify":1744813005067,"author":{"id":"3585641054025604","authorId":"3585641054025604","name":"Maxeyme","avatar":"https://static.tigerbbs.com/2f6534bff6e2d250aa9f9f44575fda56","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585641054025604","idStr":"3585641054025604"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$ </a><v-v data-views=\"0\"></v-v> ","listText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$ </a><v-v data-views=\"0\"></v-v> ","text":"$Tesla Motors(TSLA)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/425180450857416","isVote":1,"tweetType":1,"viewCount":974,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9943556528,"gmtCreate":1679579089464,"gmtModify":1679579092704,"author":{"id":"3585641054025604","authorId":"3585641054025604","name":"Maxeyme","avatar":"https://static.tigerbbs.com/2f6534bff6e2d250aa9f9f44575fda56","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585641054025604","idStr":"3585641054025604"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$ </a>.......","listText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$ </a>.......","text":"$NVIDIA Corp(NVDA)$ .......","images":[{"img":"https://community-static.tradeup.com/news/d0445808bab1c47b058919165bfa95fa","width":"1290","height":"2655"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9943556528","isVote":1,"tweetType":1,"viewCount":1884,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9085244481,"gmtCreate":1650718681379,"gmtModify":1676534781667,"author":{"id":"3585641054025604","authorId":"3585641054025604","name":"Maxeyme","avatar":"https://static.tigerbbs.com/2f6534bff6e2d250aa9f9f44575fda56","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585641054025604","idStr":"3585641054025604"},"themes":[],"htmlText":"🍎🍏","listText":"🍎🍏","text":"🍎🍏","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9085244481","repostId":"2229678171","repostType":4,"isVote":1,"tweetType":1,"viewCount":2086,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9091997271,"gmtCreate":1643760990819,"gmtModify":1676533851813,"author":{"id":"3585641054025604","authorId":"3585641054025604","name":"Maxeyme","avatar":"https://static.tigerbbs.com/2f6534bff6e2d250aa9f9f44575fda56","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585641054025604","idStr":"3585641054025604"},"themes":[],"htmlText":"20 for 1 what a great news.","listText":"20 for 1 what a great news.","text":"20 for 1 what a great news.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091997271","repostId":"2208359928","repostType":2,"isVote":1,"tweetType":1,"viewCount":1515,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9090004888,"gmtCreate":1643029875660,"gmtModify":1676533766265,"author":{"id":"3585641054025604","authorId":"3585641054025604","name":"Maxeyme","avatar":"https://static.tigerbbs.com/2f6534bff6e2d250aa9f9f44575fda56","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585641054025604","idStr":"3585641054025604"},"themes":[],"htmlText":"Best wishes to IBM holder","listText":"Best wishes to IBM holder","text":"Best wishes to IBM holder","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9090004888","repostId":"1157889578","repostType":4,"repost":{"id":"1157889578","kind":"news","pubTimestamp":1643004720,"share":"https://ttm.financial/m/news/1157889578?lang=&edition=fundamental","pubTime":"2022-01-24 14:12","market":"us","language":"en","title":"IBM Reports Its Earnings Monday. Management’s Forecasts Will Be Key.","url":"https://stock-news.laohu8.com/highlight/detail?id=1157889578","media":"Barrons","summary":"IBM will report fourth-quarter earnings after the close of trading Monday, its first financial updat","content":"<html><head></head><body><p>IBM will report fourth-quarter earnings after the close of trading Monday, its first financial update since completing the spinoff of Kyndryl, its former IT managed- services business.</p><p>Part of a multiple-step process by IBM (ticker: IBM) CEO Arvind Krishna to reset the company on a path of reliable topline growth, the Kyndryl deal was completed in the middle of November. The timing could lead to confusion about the numbers for the quarter and on adjusted data for earlier periods.</p><p>Adjusted for the Kyndryl (KD) spinoff, the Street is projecting fourth-quarter revenue of $16.1 billion, up about 2.5% from the adjusted year-ago level of $15.7 billion. The Street sees non-GAAP profits from continuing operations for the quarter of $3.14 a share, up from a spin-adjusted $1.88 a share a year earlier. IBM has said fourth-quarter revenue would be reduced by 1 or 2 percentage points due to unfavorable currency exchange rates.</p><p>IBM has previously said it expects annual growth to return to the mid-single-digits range, starting this year. The company expects over time that it will post high single-digit growth in consulting, mid-single digit growth in software and flat revenue from hardware, rising and falling with product cycles.</p><p>IBM is likely to provide more detailed guidance on the outlook for 2022, in what could be the element of the report with the most impact. The Wall Street consensus calls for revenue of $59.8 billion, with profits of $10.09 a share.</p><p>Effective this quarter, the company is rolling revised segment reporting. The business is divided into Software, which used to be called cloud and cognitive software; Consulting, formerly known as Global Business Services; and Infrastructure, which includes hardware, storage, and related support.</p><p>Evercore ISI analyst Amir Daryanani said in a recent note that all eyes will be on 2022 guidance. The Software segment could track a little below management’s long-term target, given weakness in the company’s transaction processing business, but that Consulting should its goal of growth in the high single digits, the analyst said. Hardware should show growth this year as a new mainframe cycle gets rolling, Daryanani predicted.</p><p>“We think IBM post-Kyndryl should be a much more agile and profitable asset that is better positioned to grow consistently, however we believe consensus March quarter revenue estimate appears high as mainframe refresh benefits likely won’t kick in until Q2,” he said. Daryanani kept the stock at In Line with a target of $140 for the price.</p><p>Shares closed Friday at $129.38, down 1.1%, while the S&P 500 fell 1.9%.</p><p>Stifel analyst David Grossman says a flurry of recent moves by Krishna and his team—the spinoff of Kyndryl and now the pending sale of Watson Health, expanded channel partnerships, a new sales compensation plan, and continuing acquisitions—should begin to pay off in 2022. He is projecting 6% topline growth,though the figure would be flat to up 1% excluding gains tied to exiting Kyndryl and other one-time factors.</p><p>Grossman contends that IBM’s rich 5% dividend yield suggests the market thinks IBM will remain in secular decline, no matter what Krishna does, and that current free cash flow levels aren’t sustainable. Grossman disagrees.</p><p>“While risk is elevated, given slower than expected revenue stabilization, we believe the risk/reward remains attractive, given very negative market sentiment and several potential catalysts over the next 12 months, which could drive both estimates and the multiple higher,” he wrote. Grossman has a Buy rating and $145 target price.</p></body></html>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IBM Reports Its Earnings Monday. Management’s Forecasts Will Be Key.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIBM Reports Its Earnings Monday. Management’s Forecasts Will Be Key.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-24 14:12 GMT+8 <a href=https://www.barrons.com/articles/ibm-earnings-outlook-51642799838?mod=RTA><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>IBM will report fourth-quarter earnings after the close of trading Monday, its first financial update since completing the spinoff of Kyndryl, its former IT managed- services business.Part of a ...</p>\n\n<a href=\"https://www.barrons.com/articles/ibm-earnings-outlook-51642799838?mod=RTA\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IBM":"IBM"},"source_url":"https://www.barrons.com/articles/ibm-earnings-outlook-51642799838?mod=RTA","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157889578","content_text":"IBM will report fourth-quarter earnings after the close of trading Monday, its first financial update since completing the spinoff of Kyndryl, its former IT managed- services business.Part of a multiple-step process by IBM (ticker: IBM) CEO Arvind Krishna to reset the company on a path of reliable topline growth, the Kyndryl deal was completed in the middle of November. The timing could lead to confusion about the numbers for the quarter and on adjusted data for earlier periods.Adjusted for the Kyndryl (KD) spinoff, the Street is projecting fourth-quarter revenue of $16.1 billion, up about 2.5% from the adjusted year-ago level of $15.7 billion. The Street sees non-GAAP profits from continuing operations for the quarter of $3.14 a share, up from a spin-adjusted $1.88 a share a year earlier. IBM has said fourth-quarter revenue would be reduced by 1 or 2 percentage points due to unfavorable currency exchange rates.IBM has previously said it expects annual growth to return to the mid-single-digits range, starting this year. The company expects over time that it will post high single-digit growth in consulting, mid-single digit growth in software and flat revenue from hardware, rising and falling with product cycles.IBM is likely to provide more detailed guidance on the outlook for 2022, in what could be the element of the report with the most impact. The Wall Street consensus calls for revenue of $59.8 billion, with profits of $10.09 a share.Effective this quarter, the company is rolling revised segment reporting. The business is divided into Software, which used to be called cloud and cognitive software; Consulting, formerly known as Global Business Services; and Infrastructure, which includes hardware, storage, and related support.Evercore ISI analyst Amir Daryanani said in a recent note that all eyes will be on 2022 guidance. The Software segment could track a little below management’s long-term target, given weakness in the company’s transaction processing business, but that Consulting should its goal of growth in the high single digits, the analyst said. Hardware should show growth this year as a new mainframe cycle gets rolling, Daryanani predicted.“We think IBM post-Kyndryl should be a much more agile and profitable asset that is better positioned to grow consistently, however we believe consensus March quarter revenue estimate appears high as mainframe refresh benefits likely won’t kick in until Q2,” he said. Daryanani kept the stock at In Line with a target of $140 for the price.Shares closed Friday at $129.38, down 1.1%, while the S&P 500 fell 1.9%.Stifel analyst David Grossman says a flurry of recent moves by Krishna and his team—the spinoff of Kyndryl and now the pending sale of Watson Health, expanded channel partnerships, a new sales compensation plan, and continuing acquisitions—should begin to pay off in 2022. He is projecting 6% topline growth,though the figure would be flat to up 1% excluding gains tied to exiting Kyndryl and other one-time factors.Grossman contends that IBM’s rich 5% dividend yield suggests the market thinks IBM will remain in secular decline, no matter what Krishna does, and that current free cash flow levels aren’t sustainable. Grossman disagrees.“While risk is elevated, given slower than expected revenue stabilization, we believe the risk/reward remains attractive, given very negative market sentiment and several potential catalysts over the next 12 months, which could drive both estimates and the multiple higher,” he wrote. Grossman has a Buy rating and $145 target price.","news_type":1,"symbols_score_info":{"IBM":0.9}},"isVote":1,"tweetType":1,"viewCount":2078,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9001192252,"gmtCreate":1641183092501,"gmtModify":1676533580267,"author":{"id":"3585641054025604","authorId":"3585641054025604","name":"Maxeyme","avatar":"https://static.tigerbbs.com/2f6534bff6e2d250aa9f9f44575fda56","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585641054025604","idStr":"3585641054025604"},"themes":[],"htmlText":"Accenture","listText":"Accenture","text":"Accenture","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001192252","repostId":"2200444738","repostType":4,"repost":{"id":"2200444738","kind":"highlight","pubTimestamp":1641099600,"share":"https://ttm.financial/m/news/2200444738?lang=&edition=fundamental","pubTime":"2022-01-02 13:00","market":"us","language":"en","title":"If I Could Buy Only 1 Stock in 2022, This Would Be It","url":"https://stock-news.laohu8.com/highlight/detail?id=2200444738","media":"Motley Fool","summary":"Our favorite stock picks for the coming year.","content":"<div>\n<p>We're firm believers in the benefit of owning a diversified portfolio of stocks. However, we all have our favorite stocks.We asked some of our Fool.com contributors to whittle their favorites down to ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/01/if-i-could-buy-only-1-stock-in-2022-this-would-be/\">Web Link</a>\n\n</div>\n","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>If I Could Buy Only 1 Stock in 2022, This Would Be It</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIf I Could Buy Only 1 Stock in 2022, This Would Be It\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-02 13:00 GMT+8 <a href=https://www.fool.com/investing/2022/01/01/if-i-could-buy-only-1-stock-in-2022-this-would-be/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>We're firm believers in the benefit of owning a diversified portfolio of stocks. However, we all have our favorite stocks.We asked some of our Fool.com contributors to whittle their favorites down to ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/01/if-i-could-buy-only-1-stock-in-2022-this-would-be/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BEP":"Brookfield Renewable Partners LP","BK4512":"苹果概念","BK4135":"资产管理与托管银行","MMM":"3M","BK4206":"工业集团企业","BEPC":"Brookfield Renewable Corp.","BK4133":"新能源发电业者","BAM":"布鲁克菲尔德资产管理","BK4534":"瑞士信贷持仓"},"source_url":"https://www.fool.com/investing/2022/01/01/if-i-could-buy-only-1-stock-in-2022-this-would-be/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2200444738","content_text":"We're firm believers in the benefit of owning a diversified portfolio of stocks. However, we all have our favorite stocks.We asked some of our Fool.com contributors to whittle their favorites down to their top choice to buy in 2022 if they could only pick one. Here's why 3M (NYSE:MMM), Brookfield Asset Management (NYSE:BAM), and Brookfield Renewable (NYSE:BEP)(NYSE:BEPC) topped their lists as the one stock they'd buy this year. Image source: Getty Images.A diversified giant that's still on saleReuben Gregg Brewer (3M): Benjamin Graham, renowned value investor and mentor to Warren Buffet, explains that investors are partnered with \"Mr. Market,\" a mercurial fellow prone to fits of despair and jubilation. When he's overly excited, you should consider selling to him; when he's pessimistic, you should think about buying. Right now, Mr. Market is very downbeat on diversified international industrial giant 3M. One way to see this is that the company's dividend yield, at around 3.3%, is near the top end of its historical range.MMM Dividend Yield data by YChartsGraham had some other advice when it came to actually selecting stocks. Specifically, he argued that most investors would be wise sticking to large, financially strong companies, with strong dividend histories. 3M stacks up well on these measures. It has a market cap of $100 billion, which makes it a mega-cap stock. Its balance sheet is investment-grade rated by the major credit agencies, so it's financially strong. And it has increased its dividend annually for over 60 years, making it a very elite Dividend King.So why is Mr. Market pessimistic? The answer is a mixture of slowing growth and some product and environmental lawsuits. These are notable problems, but they're not insurmountable. On the business front, the industrial giant's operations wax and wane over time just like any other company. Given its history and focus on innovation, it should eventually get back on a better track. As for the lawsuits, they could be costly, but it's likely that 3M will be able to handle the hit. In the end, this is an attractively priced name with a great history that is dealing with issues that seem transitory.A proven value creatorMatt DiLallo (Brookfield Asset Management): I like to invest. Because of that, I routinely purchase a variety of stocks. However, if I could only buy one in the coming year, Brookfield Asset Management would be my top choice.For starters, I love the company's management. CEO Bruce Flatt is a personal favorite of mine. He's right up there with Warren Buffett in my book as one of the best value investors around. I enjoy reading his quarterly letter to shareholders, which Flatt fills with investing and economic insight. He's also a proven value creator. Since becoming CEO in 2002, he's helped Brookfield deliver a 15.7% total annualized return, pulverizing the S&P 500's 10.6% total return during that time frame. I also like the company's business model. Brookfield is a leading global alternative asset manager focused on real estate, infrastructure, and renewable energy -- three of my favorite investing themes. An investment in Brookfield provides broad exposure to those three asset classes and many more. Brookfield invests directly across those themes and manages private equity funds focused on those sectors.Finally, Brookfield has enormous upside potential. It expects to double its fee-bearing assets under management over the next five years. Combine that with performance-based earnings on its funds and the compounding value of its balance sheet investments, and it has the potential of generating up to 25% annualized total returns over the next five years. That upside, along with all the other positives, is why I'd buy Brookfield if it were the only stock I could purchase this year. Investors are overlooking the growth potential hereNeha Chamaria (Brookfield Renewable): 2021 is turning out to be a record-setting year for global renewable electricity addition, but this could just be the beginning. Yet shares of one of the largest pure-play renewables companies that's growing at a steady pace have languished this year, which is why Brookfield Renewable would be at the top of my shopping list of stocks to buy in 2022.Brookfield Renewable, in fact, generated record funds from operations (FFO) in its third quarter and believes it could grow FFO by nearly 20% per year through 2026 through a combination of organic and inorganic growth. 2021 was also a solid year in terms of growth initiatives, with Brookfield Renewable expanding its U.S. distributed-generation business by nearly five times, signing agreements to acquire multiple late-stage solar development projects in the U.S. and even making meaningful headway in the high-potential green hydrogen space.Brookfield Renewable's current development pipeline is larger than ever, and the company is committed to growing dividends annually by 5% to 9%. That shouldn't be tough given the solid pace of growth in its FFO. That dividend growth, its dividend yield of 3.4%, and the humongous growth potential in renewable energy are the biggest reasons why I consider Brookfield Renewable a top stock for 2022.","news_type":1,"symbols_score_info":{"BAM":1,"MMM":1,"BEP":1,"BEPC":1}},"isVote":1,"tweetType":1,"viewCount":2211,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9009215547,"gmtCreate":1640688610316,"gmtModify":1676533534202,"author":{"id":"3585641054025604","authorId":"3585641054025604","name":"Maxeyme","avatar":"https://static.tigerbbs.com/2f6534bff6e2d250aa9f9f44575fda56","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585641054025604","idStr":"3585641054025604"},"themes":[],"htmlText":"One of the most volatile stocks of the year.","listText":"One of the most volatile stocks of the year.","text":"One of the most volatile stocks of the year.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009215547","repostId":"1138246031","repostType":2,"repost":{"id":"1138246031","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640683578,"share":"https://ttm.financial/m/news/1138246031?lang=&edition=fundamental","pubTime":"2021-12-28 17:26","market":"us","language":"en","title":"Novavax shares dropped another 4% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1138246031","media":"Tiger Newspress","summary":"Novavax shares dropped another 4% in premarket trading.The stock plunged nearly 11% yesterday.\n\nWhy ","content":"<p>Novavax shares dropped another 4% in premarket trading.The stock plunged nearly 11% yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/04a11fff9a31214bbcf7595183a5d305\" tg-width=\"843\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Why Novavax Stock Is Sinking</b></p>\n<p>The company didn't announce any new developments. So what's behind the big decline?</p>\n<p>Other vaccine stocks aren't falling nearly as much. Some were even up a little. That rules out the likelihood that declining concerns about the omicron variant played a major factor behind Novavax's drop.</p>\n<p>Instead, investors are probably growing more anxious about Novavax's planned filing for U.S. Emergency Use Authorization (EUA) of it COVID-19 vaccine NVX-CoV2373. Some investors could also be worried about the quality of Novavax's submission to the Food and Drug Administration (FDA) even if it doesn't experience another delay with the filing.</p>\n<p>CEO Stanley Erck's interview with Yahoo! Finance Live last Thursday likely didn't help reassure investors. When asked about when the FDA filing would be done, Erck replied, \"It's probably going to be next week, but I'm sticking with the claim that we'll be doing this by the end of this year.\"</p>\n<p><b>So what</b></p>\n<p>Yet another delay in a U.S. filing for NVX-CoV2373 wouldn't be catastrophic for Novavax as long as the company completes the submission soon in the new year. However, management's credibility would definitely take another big blow.</p>\n<p>But it's premature at this point to speculate that Novavax won't complete the U.S. EUA filing this week. It's also useless to fret about the quality of the company's FDA package. Novavax recently won European Union authorization for NVX-CoV2373. That shows that the vaccine maker can successfully meet regulators' manufacturing-quality hurdles.</p>\n<p><b>Now what</b></p>\n<p>Investors don't like waiting, but that's exactly what they'll have to do for now with Novavax. The company could complete its EUA filing any day now. It could also pick up new authorizations in other countries where it awaits regulatory decisions.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax shares dropped another 4% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax shares dropped another 4% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-28 17:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novavax shares dropped another 4% in premarket trading.The stock plunged nearly 11% yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/04a11fff9a31214bbcf7595183a5d305\" tg-width=\"843\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Why Novavax Stock Is Sinking</b></p>\n<p>The company didn't announce any new developments. So what's behind the big decline?</p>\n<p>Other vaccine stocks aren't falling nearly as much. Some were even up a little. That rules out the likelihood that declining concerns about the omicron variant played a major factor behind Novavax's drop.</p>\n<p>Instead, investors are probably growing more anxious about Novavax's planned filing for U.S. Emergency Use Authorization (EUA) of it COVID-19 vaccine NVX-CoV2373. Some investors could also be worried about the quality of Novavax's submission to the Food and Drug Administration (FDA) even if it doesn't experience another delay with the filing.</p>\n<p>CEO Stanley Erck's interview with Yahoo! Finance Live last Thursday likely didn't help reassure investors. When asked about when the FDA filing would be done, Erck replied, \"It's probably going to be next week, but I'm sticking with the claim that we'll be doing this by the end of this year.\"</p>\n<p><b>So what</b></p>\n<p>Yet another delay in a U.S. filing for NVX-CoV2373 wouldn't be catastrophic for Novavax as long as the company completes the submission soon in the new year. However, management's credibility would definitely take another big blow.</p>\n<p>But it's premature at this point to speculate that Novavax won't complete the U.S. EUA filing this week. It's also useless to fret about the quality of the company's FDA package. Novavax recently won European Union authorization for NVX-CoV2373. That shows that the vaccine maker can successfully meet regulators' manufacturing-quality hurdles.</p>\n<p><b>Now what</b></p>\n<p>Investors don't like waiting, but that's exactly what they'll have to do for now with Novavax. The company could complete its EUA filing any day now. It could also pick up new authorizations in other countries where it awaits regulatory decisions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138246031","content_text":"Novavax shares dropped another 4% in premarket trading.The stock plunged nearly 11% yesterday.\n\nWhy Novavax Stock Is Sinking\nThe company didn't announce any new developments. So what's behind the big decline?\nOther vaccine stocks aren't falling nearly as much. Some were even up a little. That rules out the likelihood that declining concerns about the omicron variant played a major factor behind Novavax's drop.\nInstead, investors are probably growing more anxious about Novavax's planned filing for U.S. Emergency Use Authorization (EUA) of it COVID-19 vaccine NVX-CoV2373. Some investors could also be worried about the quality of Novavax's submission to the Food and Drug Administration (FDA) even if it doesn't experience another delay with the filing.\nCEO Stanley Erck's interview with Yahoo! Finance Live last Thursday likely didn't help reassure investors. When asked about when the FDA filing would be done, Erck replied, \"It's probably going to be next week, but I'm sticking with the claim that we'll be doing this by the end of this year.\"\nSo what\nYet another delay in a U.S. filing for NVX-CoV2373 wouldn't be catastrophic for Novavax as long as the company completes the submission soon in the new year. However, management's credibility would definitely take another big blow.\nBut it's premature at this point to speculate that Novavax won't complete the U.S. EUA filing this week. It's also useless to fret about the quality of the company's FDA package. Novavax recently won European Union authorization for NVX-CoV2373. That shows that the vaccine maker can successfully meet regulators' manufacturing-quality hurdles.\nNow what\nInvestors don't like waiting, but that's exactly what they'll have to do for now with Novavax. The company could complete its EUA filing any day now. It could also pick up new authorizations in other countries where it awaits regulatory decisions.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1485,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9943556528,"gmtCreate":1679579089464,"gmtModify":1679579092704,"author":{"id":"3585641054025604","authorId":"3585641054025604","name":"Maxeyme","avatar":"https://static.tigerbbs.com/2f6534bff6e2d250aa9f9f44575fda56","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585641054025604","idStr":"3585641054025604"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$ </a>.......","listText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$ </a>.......","text":"$NVIDIA Corp(NVDA)$ .......","images":[{"img":"https://community-static.tradeup.com/news/d0445808bab1c47b058919165bfa95fa","width":"1290","height":"2655"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9943556528","isVote":1,"tweetType":1,"viewCount":1884,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9085244481,"gmtCreate":1650718681379,"gmtModify":1676534781667,"author":{"id":"3585641054025604","authorId":"3585641054025604","name":"Maxeyme","avatar":"https://static.tigerbbs.com/2f6534bff6e2d250aa9f9f44575fda56","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585641054025604","idStr":"3585641054025604"},"themes":[],"htmlText":"🍎🍏","listText":"🍎🍏","text":"🍎🍏","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9085244481","repostId":"2229678171","repostType":4,"isVote":1,"tweetType":1,"viewCount":2086,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9091997271,"gmtCreate":1643760990819,"gmtModify":1676533851813,"author":{"id":"3585641054025604","authorId":"3585641054025604","name":"Maxeyme","avatar":"https://static.tigerbbs.com/2f6534bff6e2d250aa9f9f44575fda56","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585641054025604","idStr":"3585641054025604"},"themes":[],"htmlText":"20 for 1 what a great news.","listText":"20 for 1 what a great news.","text":"20 for 1 what a great news.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091997271","repostId":"2208359928","repostType":2,"isVote":1,"tweetType":1,"viewCount":1515,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":434404581007896,"gmtCreate":1747047094273,"gmtModify":1747055860053,"author":{"id":"3585641054025604","authorId":"3585641054025604","name":"Maxeyme","avatar":"https://static.tigerbbs.com/2f6534bff6e2d250aa9f9f44575fda56","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585641054025604","idStr":"3585641054025604"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NET\">$Cloudflare, Inc.(NET)$ </a> ","listText":"<a href=\"https://ttm.financial/S/NET\">$Cloudflare, Inc.(NET)$ </a> ","text":"$Cloudflare, Inc.(NET)$","images":[{"img":"https://community-static.tradeup.com/news/b7630e523e2e2e00233e27a0b269be4f","width":"1092","height":"1717"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/434404581007896","isVote":1,"tweetType":1,"viewCount":1352,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9090004888,"gmtCreate":1643029875660,"gmtModify":1676533766265,"author":{"id":"3585641054025604","authorId":"3585641054025604","name":"Maxeyme","avatar":"https://static.tigerbbs.com/2f6534bff6e2d250aa9f9f44575fda56","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585641054025604","idStr":"3585641054025604"},"themes":[],"htmlText":"Best wishes to IBM holder","listText":"Best wishes to IBM holder","text":"Best wishes to IBM holder","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9090004888","repostId":"1157889578","repostType":4,"repost":{"id":"1157889578","kind":"news","pubTimestamp":1643004720,"share":"https://ttm.financial/m/news/1157889578?lang=&edition=fundamental","pubTime":"2022-01-24 14:12","market":"us","language":"en","title":"IBM Reports Its Earnings Monday. Management’s Forecasts Will Be Key.","url":"https://stock-news.laohu8.com/highlight/detail?id=1157889578","media":"Barrons","summary":"IBM will report fourth-quarter earnings after the close of trading Monday, its first financial updat","content":"<html><head></head><body><p>IBM will report fourth-quarter earnings after the close of trading Monday, its first financial update since completing the spinoff of Kyndryl, its former IT managed- services business.</p><p>Part of a multiple-step process by IBM (ticker: IBM) CEO Arvind Krishna to reset the company on a path of reliable topline growth, the Kyndryl deal was completed in the middle of November. The timing could lead to confusion about the numbers for the quarter and on adjusted data for earlier periods.</p><p>Adjusted for the Kyndryl (KD) spinoff, the Street is projecting fourth-quarter revenue of $16.1 billion, up about 2.5% from the adjusted year-ago level of $15.7 billion. The Street sees non-GAAP profits from continuing operations for the quarter of $3.14 a share, up from a spin-adjusted $1.88 a share a year earlier. IBM has said fourth-quarter revenue would be reduced by 1 or 2 percentage points due to unfavorable currency exchange rates.</p><p>IBM has previously said it expects annual growth to return to the mid-single-digits range, starting this year. The company expects over time that it will post high single-digit growth in consulting, mid-single digit growth in software and flat revenue from hardware, rising and falling with product cycles.</p><p>IBM is likely to provide more detailed guidance on the outlook for 2022, in what could be the element of the report with the most impact. The Wall Street consensus calls for revenue of $59.8 billion, with profits of $10.09 a share.</p><p>Effective this quarter, the company is rolling revised segment reporting. The business is divided into Software, which used to be called cloud and cognitive software; Consulting, formerly known as Global Business Services; and Infrastructure, which includes hardware, storage, and related support.</p><p>Evercore ISI analyst Amir Daryanani said in a recent note that all eyes will be on 2022 guidance. The Software segment could track a little below management’s long-term target, given weakness in the company’s transaction processing business, but that Consulting should its goal of growth in the high single digits, the analyst said. Hardware should show growth this year as a new mainframe cycle gets rolling, Daryanani predicted.</p><p>“We think IBM post-Kyndryl should be a much more agile and profitable asset that is better positioned to grow consistently, however we believe consensus March quarter revenue estimate appears high as mainframe refresh benefits likely won’t kick in until Q2,” he said. Daryanani kept the stock at In Line with a target of $140 for the price.</p><p>Shares closed Friday at $129.38, down 1.1%, while the S&P 500 fell 1.9%.</p><p>Stifel analyst David Grossman says a flurry of recent moves by Krishna and his team—the spinoff of Kyndryl and now the pending sale of Watson Health, expanded channel partnerships, a new sales compensation plan, and continuing acquisitions—should begin to pay off in 2022. He is projecting 6% topline growth,though the figure would be flat to up 1% excluding gains tied to exiting Kyndryl and other one-time factors.</p><p>Grossman contends that IBM’s rich 5% dividend yield suggests the market thinks IBM will remain in secular decline, no matter what Krishna does, and that current free cash flow levels aren’t sustainable. Grossman disagrees.</p><p>“While risk is elevated, given slower than expected revenue stabilization, we believe the risk/reward remains attractive, given very negative market sentiment and several potential catalysts over the next 12 months, which could drive both estimates and the multiple higher,” he wrote. Grossman has a Buy rating and $145 target price.</p></body></html>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IBM Reports Its Earnings Monday. Management’s Forecasts Will Be Key.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIBM Reports Its Earnings Monday. Management’s Forecasts Will Be Key.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-24 14:12 GMT+8 <a href=https://www.barrons.com/articles/ibm-earnings-outlook-51642799838?mod=RTA><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>IBM will report fourth-quarter earnings after the close of trading Monday, its first financial update since completing the spinoff of Kyndryl, its former IT managed- services business.Part of a ...</p>\n\n<a href=\"https://www.barrons.com/articles/ibm-earnings-outlook-51642799838?mod=RTA\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IBM":"IBM"},"source_url":"https://www.barrons.com/articles/ibm-earnings-outlook-51642799838?mod=RTA","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157889578","content_text":"IBM will report fourth-quarter earnings after the close of trading Monday, its first financial update since completing the spinoff of Kyndryl, its former IT managed- services business.Part of a multiple-step process by IBM (ticker: IBM) CEO Arvind Krishna to reset the company on a path of reliable topline growth, the Kyndryl deal was completed in the middle of November. The timing could lead to confusion about the numbers for the quarter and on adjusted data for earlier periods.Adjusted for the Kyndryl (KD) spinoff, the Street is projecting fourth-quarter revenue of $16.1 billion, up about 2.5% from the adjusted year-ago level of $15.7 billion. The Street sees non-GAAP profits from continuing operations for the quarter of $3.14 a share, up from a spin-adjusted $1.88 a share a year earlier. IBM has said fourth-quarter revenue would be reduced by 1 or 2 percentage points due to unfavorable currency exchange rates.IBM has previously said it expects annual growth to return to the mid-single-digits range, starting this year. The company expects over time that it will post high single-digit growth in consulting, mid-single digit growth in software and flat revenue from hardware, rising and falling with product cycles.IBM is likely to provide more detailed guidance on the outlook for 2022, in what could be the element of the report with the most impact. The Wall Street consensus calls for revenue of $59.8 billion, with profits of $10.09 a share.Effective this quarter, the company is rolling revised segment reporting. The business is divided into Software, which used to be called cloud and cognitive software; Consulting, formerly known as Global Business Services; and Infrastructure, which includes hardware, storage, and related support.Evercore ISI analyst Amir Daryanani said in a recent note that all eyes will be on 2022 guidance. The Software segment could track a little below management’s long-term target, given weakness in the company’s transaction processing business, but that Consulting should its goal of growth in the high single digits, the analyst said. Hardware should show growth this year as a new mainframe cycle gets rolling, Daryanani predicted.“We think IBM post-Kyndryl should be a much more agile and profitable asset that is better positioned to grow consistently, however we believe consensus March quarter revenue estimate appears high as mainframe refresh benefits likely won’t kick in until Q2,” he said. Daryanani kept the stock at In Line with a target of $140 for the price.Shares closed Friday at $129.38, down 1.1%, while the S&P 500 fell 1.9%.Stifel analyst David Grossman says a flurry of recent moves by Krishna and his team—the spinoff of Kyndryl and now the pending sale of Watson Health, expanded channel partnerships, a new sales compensation plan, and continuing acquisitions—should begin to pay off in 2022. He is projecting 6% topline growth,though the figure would be flat to up 1% excluding gains tied to exiting Kyndryl and other one-time factors.Grossman contends that IBM’s rich 5% dividend yield suggests the market thinks IBM will remain in secular decline, no matter what Krishna does, and that current free cash flow levels aren’t sustainable. Grossman disagrees.“While risk is elevated, given slower than expected revenue stabilization, we believe the risk/reward remains attractive, given very negative market sentiment and several potential catalysts over the next 12 months, which could drive both estimates and the multiple higher,” he wrote. Grossman has a Buy rating and $145 target price.","news_type":1,"symbols_score_info":{"IBM":0.9}},"isVote":1,"tweetType":1,"viewCount":2078,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":442838974001216,"gmtCreate":1749137299634,"gmtModify":1749138476027,"author":{"id":"3585641054025604","authorId":"3585641054025604","name":"Maxeyme","avatar":"https://static.tigerbbs.com/2f6534bff6e2d250aa9f9f44575fda56","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585641054025604","idStr":"3585641054025604"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NET\">$Cloudflare, Inc.(NET)$ </a> ","listText":"<a href=\"https://ttm.financial/S/NET\">$Cloudflare, Inc.(NET)$ </a> ","text":"$Cloudflare, Inc.(NET)$","images":[{"img":"https://community-static.tradeup.com/news/4a8970fd80df2bd90233e5c969a28e4e","width":"1092","height":"1717"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/442838974001216","isVote":1,"tweetType":1,"viewCount":1290,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":442835938181688,"gmtCreate":1749136845035,"gmtModify":1749138475033,"author":{"id":"3585641054025604","authorId":"3585641054025604","name":"Maxeyme","avatar":"https://static.tigerbbs.com/2f6534bff6e2d250aa9f9f44575fda56","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585641054025604","idStr":"3585641054025604"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NET\">$Cloudflare, Inc.(NET)$ </a> ","listText":"<a href=\"https://ttm.financial/S/NET\">$Cloudflare, Inc.(NET)$ </a> ","text":"$Cloudflare, Inc.(NET)$","images":[{"img":"https://community-static.tradeup.com/news/f0d3aa65f643a222b488af45efbe840b","width":"1092","height":"1717"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/442835938181688","isVote":1,"tweetType":1,"viewCount":1082,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":434406816539392,"gmtCreate":1747047180179,"gmtModify":1747047185033,"author":{"id":"3585641054025604","authorId":"3585641054025604","name":"Maxeyme","avatar":"https://static.tigerbbs.com/2f6534bff6e2d250aa9f9f44575fda56","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585641054025604","idStr":"3585641054025604"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/GOOGL\">$Alphabet(GOOGL)$ </a> ","listText":"<a href=\"https://ttm.financial/S/GOOGL\">$Alphabet(GOOGL)$ </a> ","text":"$Alphabet(GOOGL)$","images":[{"img":"https://community-static.tradeup.com/news/3c7e94bf705712cd6c9ee5e71719e7be","width":"1092","height":"1717"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/434406816539392","isVote":1,"tweetType":1,"viewCount":1022,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":425180450857416,"gmtCreate":1744813001442,"gmtModify":1744813005067,"author":{"id":"3585641054025604","authorId":"3585641054025604","name":"Maxeyme","avatar":"https://static.tigerbbs.com/2f6534bff6e2d250aa9f9f44575fda56","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585641054025604","idStr":"3585641054025604"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$ </a><v-v data-views=\"0\"></v-v> ","listText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$ </a><v-v data-views=\"0\"></v-v> ","text":"$Tesla Motors(TSLA)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/425180450857416","isVote":1,"tweetType":1,"viewCount":974,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9001192252,"gmtCreate":1641183092501,"gmtModify":1676533580267,"author":{"id":"3585641054025604","authorId":"3585641054025604","name":"Maxeyme","avatar":"https://static.tigerbbs.com/2f6534bff6e2d250aa9f9f44575fda56","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585641054025604","idStr":"3585641054025604"},"themes":[],"htmlText":"Accenture","listText":"Accenture","text":"Accenture","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001192252","repostId":"2200444738","repostType":4,"repost":{"id":"2200444738","kind":"highlight","pubTimestamp":1641099600,"share":"https://ttm.financial/m/news/2200444738?lang=&edition=fundamental","pubTime":"2022-01-02 13:00","market":"us","language":"en","title":"If I Could Buy Only 1 Stock in 2022, This Would Be It","url":"https://stock-news.laohu8.com/highlight/detail?id=2200444738","media":"Motley Fool","summary":"Our favorite stock picks for the coming year.","content":"<div>\n<p>We're firm believers in the benefit of owning a diversified portfolio of stocks. However, we all have our favorite stocks.We asked some of our Fool.com contributors to whittle their favorites down to ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/01/if-i-could-buy-only-1-stock-in-2022-this-would-be/\">Web Link</a>\n\n</div>\n","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>If I Could Buy Only 1 Stock in 2022, This Would Be It</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIf I Could Buy Only 1 Stock in 2022, This Would Be It\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-02 13:00 GMT+8 <a href=https://www.fool.com/investing/2022/01/01/if-i-could-buy-only-1-stock-in-2022-this-would-be/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>We're firm believers in the benefit of owning a diversified portfolio of stocks. However, we all have our favorite stocks.We asked some of our Fool.com contributors to whittle their favorites down to ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/01/if-i-could-buy-only-1-stock-in-2022-this-would-be/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BEP":"Brookfield Renewable Partners LP","BK4512":"苹果概念","BK4135":"资产管理与托管银行","MMM":"3M","BK4206":"工业集团企业","BEPC":"Brookfield Renewable Corp.","BK4133":"新能源发电业者","BAM":"布鲁克菲尔德资产管理","BK4534":"瑞士信贷持仓"},"source_url":"https://www.fool.com/investing/2022/01/01/if-i-could-buy-only-1-stock-in-2022-this-would-be/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2200444738","content_text":"We're firm believers in the benefit of owning a diversified portfolio of stocks. However, we all have our favorite stocks.We asked some of our Fool.com contributors to whittle their favorites down to their top choice to buy in 2022 if they could only pick one. Here's why 3M (NYSE:MMM), Brookfield Asset Management (NYSE:BAM), and Brookfield Renewable (NYSE:BEP)(NYSE:BEPC) topped their lists as the one stock they'd buy this year. Image source: Getty Images.A diversified giant that's still on saleReuben Gregg Brewer (3M): Benjamin Graham, renowned value investor and mentor to Warren Buffet, explains that investors are partnered with \"Mr. Market,\" a mercurial fellow prone to fits of despair and jubilation. When he's overly excited, you should consider selling to him; when he's pessimistic, you should think about buying. Right now, Mr. Market is very downbeat on diversified international industrial giant 3M. One way to see this is that the company's dividend yield, at around 3.3%, is near the top end of its historical range.MMM Dividend Yield data by YChartsGraham had some other advice when it came to actually selecting stocks. Specifically, he argued that most investors would be wise sticking to large, financially strong companies, with strong dividend histories. 3M stacks up well on these measures. It has a market cap of $100 billion, which makes it a mega-cap stock. Its balance sheet is investment-grade rated by the major credit agencies, so it's financially strong. And it has increased its dividend annually for over 60 years, making it a very elite Dividend King.So why is Mr. Market pessimistic? The answer is a mixture of slowing growth and some product and environmental lawsuits. These are notable problems, but they're not insurmountable. On the business front, the industrial giant's operations wax and wane over time just like any other company. Given its history and focus on innovation, it should eventually get back on a better track. As for the lawsuits, they could be costly, but it's likely that 3M will be able to handle the hit. In the end, this is an attractively priced name with a great history that is dealing with issues that seem transitory.A proven value creatorMatt DiLallo (Brookfield Asset Management): I like to invest. Because of that, I routinely purchase a variety of stocks. However, if I could only buy one in the coming year, Brookfield Asset Management would be my top choice.For starters, I love the company's management. CEO Bruce Flatt is a personal favorite of mine. He's right up there with Warren Buffett in my book as one of the best value investors around. I enjoy reading his quarterly letter to shareholders, which Flatt fills with investing and economic insight. He's also a proven value creator. Since becoming CEO in 2002, he's helped Brookfield deliver a 15.7% total annualized return, pulverizing the S&P 500's 10.6% total return during that time frame. I also like the company's business model. Brookfield is a leading global alternative asset manager focused on real estate, infrastructure, and renewable energy -- three of my favorite investing themes. An investment in Brookfield provides broad exposure to those three asset classes and many more. Brookfield invests directly across those themes and manages private equity funds focused on those sectors.Finally, Brookfield has enormous upside potential. It expects to double its fee-bearing assets under management over the next five years. Combine that with performance-based earnings on its funds and the compounding value of its balance sheet investments, and it has the potential of generating up to 25% annualized total returns over the next five years. That upside, along with all the other positives, is why I'd buy Brookfield if it were the only stock I could purchase this year. Investors are overlooking the growth potential hereNeha Chamaria (Brookfield Renewable): 2021 is turning out to be a record-setting year for global renewable electricity addition, but this could just be the beginning. Yet shares of one of the largest pure-play renewables companies that's growing at a steady pace have languished this year, which is why Brookfield Renewable would be at the top of my shopping list of stocks to buy in 2022.Brookfield Renewable, in fact, generated record funds from operations (FFO) in its third quarter and believes it could grow FFO by nearly 20% per year through 2026 through a combination of organic and inorganic growth. 2021 was also a solid year in terms of growth initiatives, with Brookfield Renewable expanding its U.S. distributed-generation business by nearly five times, signing agreements to acquire multiple late-stage solar development projects in the U.S. and even making meaningful headway in the high-potential green hydrogen space.Brookfield Renewable's current development pipeline is larger than ever, and the company is committed to growing dividends annually by 5% to 9%. That shouldn't be tough given the solid pace of growth in its FFO. That dividend growth, its dividend yield of 3.4%, and the humongous growth potential in renewable energy are the biggest reasons why I consider Brookfield Renewable a top stock for 2022.","news_type":1,"symbols_score_info":{"BAM":1,"MMM":1,"BEP":1,"BEPC":1}},"isVote":1,"tweetType":1,"viewCount":2211,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9009215547,"gmtCreate":1640688610316,"gmtModify":1676533534202,"author":{"id":"3585641054025604","authorId":"3585641054025604","name":"Maxeyme","avatar":"https://static.tigerbbs.com/2f6534bff6e2d250aa9f9f44575fda56","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585641054025604","idStr":"3585641054025604"},"themes":[],"htmlText":"One of the most volatile stocks of the year.","listText":"One of the most volatile stocks of the year.","text":"One of the most volatile stocks of the year.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009215547","repostId":"1138246031","repostType":2,"repost":{"id":"1138246031","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640683578,"share":"https://ttm.financial/m/news/1138246031?lang=&edition=fundamental","pubTime":"2021-12-28 17:26","market":"us","language":"en","title":"Novavax shares dropped another 4% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1138246031","media":"Tiger Newspress","summary":"Novavax shares dropped another 4% in premarket trading.The stock plunged nearly 11% yesterday.\n\nWhy ","content":"<p>Novavax shares dropped another 4% in premarket trading.The stock plunged nearly 11% yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/04a11fff9a31214bbcf7595183a5d305\" tg-width=\"843\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Why Novavax Stock Is Sinking</b></p>\n<p>The company didn't announce any new developments. So what's behind the big decline?</p>\n<p>Other vaccine stocks aren't falling nearly as much. Some were even up a little. That rules out the likelihood that declining concerns about the omicron variant played a major factor behind Novavax's drop.</p>\n<p>Instead, investors are probably growing more anxious about Novavax's planned filing for U.S. Emergency Use Authorization (EUA) of it COVID-19 vaccine NVX-CoV2373. Some investors could also be worried about the quality of Novavax's submission to the Food and Drug Administration (FDA) even if it doesn't experience another delay with the filing.</p>\n<p>CEO Stanley Erck's interview with Yahoo! Finance Live last Thursday likely didn't help reassure investors. When asked about when the FDA filing would be done, Erck replied, \"It's probably going to be next week, but I'm sticking with the claim that we'll be doing this by the end of this year.\"</p>\n<p><b>So what</b></p>\n<p>Yet another delay in a U.S. filing for NVX-CoV2373 wouldn't be catastrophic for Novavax as long as the company completes the submission soon in the new year. However, management's credibility would definitely take another big blow.</p>\n<p>But it's premature at this point to speculate that Novavax won't complete the U.S. EUA filing this week. It's also useless to fret about the quality of the company's FDA package. Novavax recently won European Union authorization for NVX-CoV2373. That shows that the vaccine maker can successfully meet regulators' manufacturing-quality hurdles.</p>\n<p><b>Now what</b></p>\n<p>Investors don't like waiting, but that's exactly what they'll have to do for now with Novavax. The company could complete its EUA filing any day now. It could also pick up new authorizations in other countries where it awaits regulatory decisions.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax shares dropped another 4% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax shares dropped another 4% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-28 17:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novavax shares dropped another 4% in premarket trading.The stock plunged nearly 11% yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/04a11fff9a31214bbcf7595183a5d305\" tg-width=\"843\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Why Novavax Stock Is Sinking</b></p>\n<p>The company didn't announce any new developments. So what's behind the big decline?</p>\n<p>Other vaccine stocks aren't falling nearly as much. Some were even up a little. That rules out the likelihood that declining concerns about the omicron variant played a major factor behind Novavax's drop.</p>\n<p>Instead, investors are probably growing more anxious about Novavax's planned filing for U.S. Emergency Use Authorization (EUA) of it COVID-19 vaccine NVX-CoV2373. Some investors could also be worried about the quality of Novavax's submission to the Food and Drug Administration (FDA) even if it doesn't experience another delay with the filing.</p>\n<p>CEO Stanley Erck's interview with Yahoo! Finance Live last Thursday likely didn't help reassure investors. When asked about when the FDA filing would be done, Erck replied, \"It's probably going to be next week, but I'm sticking with the claim that we'll be doing this by the end of this year.\"</p>\n<p><b>So what</b></p>\n<p>Yet another delay in a U.S. filing for NVX-CoV2373 wouldn't be catastrophic for Novavax as long as the company completes the submission soon in the new year. However, management's credibility would definitely take another big blow.</p>\n<p>But it's premature at this point to speculate that Novavax won't complete the U.S. EUA filing this week. It's also useless to fret about the quality of the company's FDA package. Novavax recently won European Union authorization for NVX-CoV2373. That shows that the vaccine maker can successfully meet regulators' manufacturing-quality hurdles.</p>\n<p><b>Now what</b></p>\n<p>Investors don't like waiting, but that's exactly what they'll have to do for now with Novavax. The company could complete its EUA filing any day now. It could also pick up new authorizations in other countries where it awaits regulatory decisions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138246031","content_text":"Novavax shares dropped another 4% in premarket trading.The stock plunged nearly 11% yesterday.\n\nWhy Novavax Stock Is Sinking\nThe company didn't announce any new developments. So what's behind the big decline?\nOther vaccine stocks aren't falling nearly as much. Some were even up a little. That rules out the likelihood that declining concerns about the omicron variant played a major factor behind Novavax's drop.\nInstead, investors are probably growing more anxious about Novavax's planned filing for U.S. Emergency Use Authorization (EUA) of it COVID-19 vaccine NVX-CoV2373. Some investors could also be worried about the quality of Novavax's submission to the Food and Drug Administration (FDA) even if it doesn't experience another delay with the filing.\nCEO Stanley Erck's interview with Yahoo! Finance Live last Thursday likely didn't help reassure investors. When asked about when the FDA filing would be done, Erck replied, \"It's probably going to be next week, but I'm sticking with the claim that we'll be doing this by the end of this year.\"\nSo what\nYet another delay in a U.S. filing for NVX-CoV2373 wouldn't be catastrophic for Novavax as long as the company completes the submission soon in the new year. However, management's credibility would definitely take another big blow.\nBut it's premature at this point to speculate that Novavax won't complete the U.S. EUA filing this week. It's also useless to fret about the quality of the company's FDA package. Novavax recently won European Union authorization for NVX-CoV2373. That shows that the vaccine maker can successfully meet regulators' manufacturing-quality hurdles.\nNow what\nInvestors don't like waiting, but that's exactly what they'll have to do for now with Novavax. The company could complete its EUA filing any day now. It could also pick up new authorizations in other countries where it awaits regulatory decisions.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1485,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}